Eribulin in metastatic breast cancer: Real world data

Article type: Research Article

Authors: Fernández-Laguna, Clara Luz^a; | Maray, Ivan^a | Macia-Rivas, Lola^a | Álvarez-Asteinza, Cristina^a | Fernández-Lastras, Sergio^a | Velasco Durántez, Veronica^b | Carbajales Álvarez, Mónica^a | Lozano-Blázquez, Ana^a

Affiliations: [a] Department of Pharmacy, Hospital Universitario Central de Asturias, Oviedo, Spain | [b] Department of Oncology, Hospital Universitario de Cabueñes, Gijon, Spain

Correspondence: [*] Corresponding author: Clara Luz Fernández-Laguna, Department of Pharmacy, Hospital Universitario Central de Asturias. Av Roma s/n 33011, Oviedo, Spain. Tel.:+34 6525670990; E-mail: [email protected]. ORCID: https://orcid.org/0000-0001-5909-5639

Abstract: BACKGROUND:Metastatic breast cancer (MBC) is incurable. Systemic therapy is the standard treatment; however, an optimal sequence of chemotherapy has not been established. OBJECTIVE:Evaluating effectiveness and safety of eribulin in MBC treatment and comparing the results obtained with published literature. METHODS:Observational, descriptive and retrospective study of patients with MBC treated with eribulin from 01/12/2015 to 30/10/2021. Effectiveness was analysed using Kaplan–Meier-survival-curves, for the overall number of patients treated and stratified by treatment line. Safety was measured according to adverse events (AE) based on CTCAE v5.0. Data analysis was performed using R v4.0.1. RESULTS:They were included in this study 53 women who received eribulin (median age 58 years). Comparison of median survival from this study versus published data were: progression-free-survival (PFS) 3 (IC95%: 3–4) versus 3.7 months and overall-survival (OS) 8 (IC95%: 3–4) versus 13.2 months for the overall number of patients. For the 1–3 line treatment group, PFS was 6 (IC95%: 3-NA) and OS was 15 (IC95%: 6-NA). There were 322 AEs, the most frequent being blood disorders 16% (52), general disorders 12% (38), and gastrointestinal disorders 12% (38). CONCLUSIONS:The median PFS was similar to that reported previously, with lower OS. There was a tendency to achieve better results when eribulin was used earlier. Eribulin is a less well-tolerated drug than published literature.

Keywords: Eribulin, metastatic breast cancer, effectiveness, safety, Real world data

DOI: 10.3233/BD-230031

Journal: Breast Disease, vol. 42, no. 1, pp. 349-360, 2023